Shionogi takes InterMune to US court, claiming unpaid EU royalties for Esbriet
This article was originally published in Scrip
Shionogi has lodged a legal action in the US against InterMune, claiming that the US firm has failed to pay due royalties on sales of the idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone) in the EU.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
Tislelizumab meets overall survival endpoint in later-line NSCLC at planned interim analysis, but faces exploding competition in the Chinese immuno-oncology sector.